Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-6-3
pubmed:abstractText
Vascular endothelial cell growth factor (VEGF) plays an important role in the processes of angiogenesis. Angiogenesis appears to be essential for the growth of solid tumors and their metastasis. VEGF plays a principal role in tumor angiogenesis. To identify a compound that inhibits the binding of VEGF to its receptor, we used a high-throughput screening method and found that oxydibenzoic acid derivatives inhibited VEGF binding to its receptors. Among the active compounds, 5-[3-[4-(octadecyloxy)phenyl]propionylamino]-2,4'-oxydibenzoic acid (VGA1102) was selected based on its potent binding inhibitory activity. VGA1102 inhibited [(125)I]VEGF binding to both of two VEGF receptor-transfected cell lines, NIH-Flt-1 and NIH-KDR/Flk-1, in a concentration-dependent manner, with IC(50) values of 0.66+/-0.07 and 0.61+/-0.16 micro M, respectively. VGA1102 (10 micro M) exhibited inhibitory activity against VEGF-induced receptor autophosphorylation. VGA1102 also inhibited VEGF-induced growth of rat liver sinusoidal endothelial cells (IC(50)=0.89+/-0.16 micro M) as well as VEGF-induced tube formation of HUVEC in vitro. VGA1102 reduced intradermal VEGF-induced vascular permeability in guinea pigs. Treatment with VGA1102 (50 mg/kg, i.p., days 0-20) significantly increased the lifespan of MM2-bearing mice with an increase in lifespan of >195.8%, and all such mice were long-term survivors on day 71. Furthermore, VGA1102 (50 mg/kg, i.p.) administered daily suppressed the growth of nude mice transplanted with LC-6 human non-small-cell lung cancer. These results suggest that VGA1102 inhibits VEGF function resulting in inhibition of tumor angiogenesis, which led to suppression of growth of human tumors transplanted into nude mice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
16-24
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15064856-Alkanes, pubmed-meshheading:15064856-Angiogenesis Inhibitors, pubmed-meshheading:15064856-Animals, pubmed-meshheading:15064856-Benzoic Acids, pubmed-meshheading:15064856-Capillary Permeability, pubmed-meshheading:15064856-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:15064856-Cell Division, pubmed-meshheading:15064856-Cell Line, pubmed-meshheading:15064856-Guinea Pigs, pubmed-meshheading:15064856-Infusions, Parenteral, pubmed-meshheading:15064856-Lung Neoplasms, pubmed-meshheading:15064856-Mice, pubmed-meshheading:15064856-Mice, Inbred BALB C, pubmed-meshheading:15064856-Mice, Nude, pubmed-meshheading:15064856-Molecular Weight, pubmed-meshheading:15064856-Neoplasms, Experimental, pubmed-meshheading:15064856-Neovascularization, Pathologic, pubmed-meshheading:15064856-Rats, pubmed-meshheading:15064856-Rats, Wistar, pubmed-meshheading:15064856-Receptors, Vascular Endothelial Growth Factor, pubmed-meshheading:15064856-Survival Analysis, pubmed-meshheading:15064856-Transplantation, Heterologous, pubmed-meshheading:15064856-Vascular Endothelial Growth Factor A
pubmed:year
2004
pubmed:articleTitle
A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
pubmed:affiliation
Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, 331-9530 Saitama, Japan. y.ueda@po.rd.taisho.co.jp
pubmed:publicationType
Journal Article